Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program; Says On-Going Collaboration With UCB Remains Highly Productive
October 12, 2015 at 16:22 PM EDT
Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to ...
